Lifesaving care requires timely information that enables sound decision-making. ZOLL Data Solutions provide real-time feedback and predictive analytics that help optimize patient care, outcomes, and revenue.
Learn more about our software and data products
You need a monitor/defibrillator that’s nimble and can keep pace with evolving pre-hospital care standards. The ZOLL X Series Advanced is the first device of its kind to feature real-time ventilation feedback, telemedicine capabilities, and post-case performance data review.
Give patients every bit of oxygen they need while en route to the hospital. Z Vent is an energy-efficient transport ventilator that delivers oxygen for hours — even under the most challenging circumstances.
You can deliver resuscitation on the move — even in an unstable environment. The AutoPulse system is the only device of its kind that mechanically squeezes a patient’s chest when it is not safe or possible to manually deliver CPR.
R Series devices help you consistently deliver high-quality CPR, provide optimal defibrillation and pacing treatments, and manage your data to address critical quality improvements. Plus, these devices feature easy-to-use technology designed to enhance your patient outcomes.
Even when a scene presents you with challenges, manage a cardiac arrest event more effectively than ever before with AutoPulse NXT. Quickly begin patient-customized, high-quality compressions in the field that can continue through transport and treatment.
The more data you have, the better the chance of a successful outcome. The AED Pro defibrillator has a configurable display and shows a patient’s underlying heart rhythm during CPR.
The Propaq® MD is a lightweight, compact, transport monitor/defibrillator. It provides advanced monitoring and resuscitation capabilities, with decision support and telemedicine technology.
ZOLL announced today that its TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier, Inc., effective as of July 1, 2022. The agreement allows Premier hospital members, at their discretion, to take advantage of special pricing and pre-negotiated terms to access SSO2 Therapy for their ST-segment elevation (STEMI) heart attack patients.
TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agree ZOLL has been selected to exhibit SuperSaturated Oxygen (SSO2) Therapy, which delivers high levels of dissolved oxygen directly to the heart following severe heart attack, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17 in Dallas.ment for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier, Inc., effective as of July 1, 2022. The agreement allows Premier hospital members, at their discretion, to take advantage of special pricing and pre-negotiated terms to access SSO2 Therapy for their ST-segment elevation (STEMI) heart attack patients.
ZOLL announced today that the first patient has enrolled in the AMIHOT III post-approval study further evaluating TherOx® SuperSaturated Oxygen (SSO2) Therapy for the treatment of the most severe form of heart attack, left anterior descending (LAD) ST-Elevation Myocardial Infarction (STEMI). The patient, treated at WakeMed Health & Hospitals in North Carolina, received SSO2 Therapy, the first FDA-approved therapy shown to significantly reduce the size of damaged tissue (infarct) following percutaneous coronary intervention (PCI).